Background Tumor relapse due to mutation in CD19 can hinder the efficacy of chimeric antigen receptor (CAR)-T cell therapy. Herein, we focused on lymphoma patients whose B cells exhibited a point mutation in CD19 of B cells after CAR-T cell infusion.
Methods The CAR-T and CD19+ B cells from peripheral blood or bone marrow were assessed using flow cytometry. Genome sequencing was conducted to identify the molecular characteristics of CAR-T and CD19+ B cells from pre-relapse and postrelapse samples. CD19 in CARs comprising single chain fragments variable (scFV) antibody with FMC63 or 21D4 was constructed. The cytotoxic efficacy of CAR-T cells was also evaluated via in vitro and in vivo experiments.
Results A patient with high-grade B cell lymphoma exhibited complete response, but the lymphoma relapsed in her left breast at 6 months after CD19 CAR (FMC63)-T cell infusion. A mutation was found in exon 3 of CD19 (p.163. R-L) in malignant B cells of the patient. In two lymphoma patients who exhibited resistance to CAR-T cell therapy, a mutation was detected in exon 3 of CD19 (p.174. L-V). Functional analysis revealed that FMC63 CAR-T cells exhibited antitumor ability against wild-type CD19+ cells but were unable to eradicate these two types of mutated CD19+ cells. Interestingly, 21D4 CAR-T cells were potentially capable of eradicating these mutated CD19+ cells and exhibiting high antitumor capacity against CD19+ cells with loss of exon 1, 2, or 3.
Conclusions These findings suggest that point mutation can facilitate immune escape from CAR-T cell therapy and that alternative CAR-T cells can effectively eradicate the mutated B cells, providing an individualized therapeutic approach for lymphoma patients showing relapse.
- adaptive immunity
- cell engineering
- hematologic neoplasms
This is an open access article distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited, appropriate credit is given, any changes made indicated, and the use is non-commercial. See http://creativecommons.org/licenses/by-nc/4.0/.
Statistics from Altmetric.com
If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.
Cancer immunotherapy based on chimeric antigen receptor (CAR)-T cells against CD19 has been used successfully to treat B-cell malignancies.1 2 Unfortunately, a significant number of responding patients have been reported to eventually exhibit relapse.3 Recently, there are two major types of relapse were reported, including antigen loss (CD19−) and positive (CD19+), following analysis of CD19 expression in B cells by using clinical flow cytometry. An estimated 20%–30% of relapses after CD19 CAR-T cell therapy are attributed to the antigen loss, indicating an urgent need for investigating the mechanisms underlying recurrence and for improving the efficacy of CAR-T cell therapy.4 5 Interestingly, one of the specific mechanisms of tumor escape that has been reported suggests that exon mutations affecting the CD19 gene and its splicing isoforms, leading to the disappearance of CD19 epitope that is recognized by the FMC63-based antigen-binding moiety of CD19 CAR.6 Other mechanisms, such as induction of a myeloid switch in the B-cell acute lymphoblastic leukemia (ALL) patients with rearrangements of the mixed lineage leukemia (MLL) gene or the persistence of minor CD19− clones have also been reported.7 8 Dual CARs targeting two different antigens, namely CD19 and CD123, represent an effective strategy to prevent antigen-loss associated relapses.4 In the CD19+ relapsed patients, CD19 remains present on the B-ALL cell surface, while the CAR-T cells can become exhausted in vivo.9 10 Moreover, these patients still have a poor prognosis with re-infusion of autologous CAR-T cells.11 A rare case has been reported in which the CAR gene was transduced into a single leukemic B cell during CTL019 (tisagenlecleucel, Kymriah, Novartis) generation and the CD19 CAR expression directly mediated the loss of CD19 in leukemia cells, thereby hindering its detection by standardized flow cytometry. CD19 transcripts and specific proteins are preserved and resistant to CD22 CAR-T cell therapy.12 Furthermore, there are few reports on CD19+ relapse in lymphoma patients, and the strategy to overcome this issue is still not well defined.
In this study, we have reported a 24-year-old female patient with high-grade B cell lymphoma (HGBCL) who achieved complete response (CR) after being treated with autologous CD19 CAR (FMC63)-T cells. Unfortunately, CD19+ relapse occurred in her left breast after 6 months, which was associated with a point mutation in exon 3 of CD19. Despite the continuous generation of CAR-T cells possessing antitumor function against wild type CD19+ B cells, they could not eradicate the mutated CD19+ cells in vivo. Interestingly, another CD19 CAR, namely 21D4, transduced T-cells exhibited a more enhanced antitumor capacity to eradicate the mutated CD19+ cells or exon 1-deleted, 2-deleted, or 3-deleted H322-CD19 cells than that of FMC63 CAR-T cells. Moreover, we found no mutation in CD19+ tumor cells from bone marrow of one lymphoma patient who exhibited long-term remission after CAR-T cell therapy. Conversely, a point mutation was detected in CD19+ cells from samples of lymphoma samples who had no response (NR) to autologous FMC63 CAR-T cells, but these mutated B cells could be killed by 21D4 CAR-T cells, indicating the potential of 21D4 CAR-T cells in treatment of patients with CD19 mutations.
The clinical trial in which patients with B cell malignancies participated was conducted at the First Affiliated Hospital of Zhengzhou University and has been reported previously (ClinicalTrials.gov number, NCT03156101).13 End points for this study included safety, overall survival, duration of response, and CD19 CAR-T cellular kinetics. These patients were subjected to lymphodepleting chemotherapy with fludarabine (25 mg/m2 body surface area per day) for 3 days, and cyclophosphamide (500 mg/m2 body surface area per day) for 2 days, followed by infusion of CD19 CAR-T cells after 3–5 days. Peripheral blood and bone marrow samples were drawn to evaluate the CAR-T and CD19+ B cells kinetics. Sequencing of RNA (RNA-seq) and DNA (DNA-seq) was performed to evaluate the CAR-T function and mutation of B cells. Positron emission tomography (PET)-CT or CT was performed to evaluate the overall disease burden. Production of CAR-expressing T cells were produced for the experiments as previously described.13 Patients and healthy donors provided written informed consents according to the Declaration of Helsinki presented at the International Conference on Harmonization Guidelines for Good Clinical Practice. All relevant ethical regulations were followed in this study.
Lentiviral constructs and CAR-T cell generation
CD19 CARs comprising a single chain fragment variable (scFv) derived from clone FMC63 or 21D4, 4-1BB (CD137) costimulatory, and CD3-zeta domains were generated as previously described.13 Peripheral blood samples drawn from patients or healthy donors were used to produce CD19 CAR-T cells. The transduced T-cells were cultured for about 10 days and the transduction efficiency was evaluated by flow cytometry before conducting infusion.
To generate CD19 or mutated CD19 (p.163. R-L) expressing vectors, the complete gene as well as the CD19 exon 1, 2, 3, or 4 deleted versions were synthesized commercially (Sheng gong, Shanghai) and cloned into pCDH-EF1-IRES-Puro vector. Lentiviral particles were generated by transfection of the above-mentioned constructs into 293 T cells using Lipofectamine-2000 (Invitrogen). Viral supernatants were harvested 48 hours post-transfection and used to infect luciferase expressing H322 or A549 cell lines in the presence of polybrene (4 µg/mL).
A549, H322, 293T, and Raji cell lines were obtained from the Cell Bank of the Chinese Academy of Sciences. Cell lines were cultured in DMEM (Gibco) supplemented with 10% fetal bovine serum (FBS; Hyclone) and antibiotics (Penicillin and Streptomycin; Gibco) at 37°C with a continuous supply of 5% CO2. These cells were then infected with pLenti-CMV-luc2-IRES-Puro virus to express the firefly luciferase.
Peripheral blood mononuclear cells (PBMCs) were isolated from the peripheral blood samples drawn from patients. Briefly, 1×106 cells were washed with phosphate-buffered saline (PBS) and resuspended in fluorescence activated cell sorting (FACS) buffer consisting of PBS and 2% FBS. Cells were then incubated with anti-CD3-PE-cy7 (clone UCHT1; BD Pharmingen), CD19 (20-291) protein-FITC (ACRO Biosystems), or anti-CD19-PE (clone HIB19; BioLegend) antibodies for 30 min. Flow cytometry analysis was performed on BD FACS CantoII (BD, USA).
The ability of CD19 CAR-T cells (FMC63 or 21D4) to kill the target cells expressing CD19 was evaluated by flow cytometry or bioluminescent imaging (BLI) using the IVIS Spectrum Imaging System (PerkinElemer). Approximately 3×104 CD19+ cells from bone marrow pre-infusion and postinfusion of CAR-T cells, CD19-H322 cells, CD19-A549 cells, mutated CD19 (p.163. R-L)-H322 cells, mutated CD19 (p.163. R-L)-A549 cells, and exon 1-deleted, 2-deleted, 3-deleted, or 4-deleted H322-CD19 cells were incubated with CAR-T cells for 6 or 24 hours at various effector:target (E:T) ratios. The lysis of target cells was determined by Annexin-V-PI staining. The BLI was performed and the viabilities of target cells were determined based on their photon intensities. Tumor cells alone were used as the control.
Quantitative real-time PCR
Genomic DNA was isolated from PBMCs that were collected before the treatment and at multiple time-points after treatment by using the DNeasy blood & tissue kit (Qiagen). The kinetics of CAR-modified cells in vivo was assessed using validated PCR primers specific to the 4-1BB and CD3ζ fusion gene as previously described.14 15
CAR-T cells generated from PBMCs before infusion and at day 14 and 180 post-treatment were collected by using the cell sorter Moflo-XDP (Beckman-Coulter). CD19+ cells from bone marrow or tumor tissues before treatment and at days 7 and 180 post-treatment were collected to evaluate the molecular characteristics of B cells. Total RNA was isolated using TRIzol reagent (Invitrogen) and treated with RNase-free DNaseI at 37°C for 20 min. Integrity of RNA was assessed on the Agilent TapeStation (RIN), followed by preparation for sequencing using the TruSeq RNA v2 prep (Illumina) as previously described.12 RNA-sequencing and data analysis were performed at BGI (Wuhan, China).
Genomic DNA was extracted from the bone marrow or tumor tissue according to manufacturer’s instructions (Promega).16 17 The enriched DNA fragments were sheared to 150–200 bp fragments on an average and were subjected to standard Illumina Genome Analyzer library preparation according to manufacturer’s protocol. High-quality reads were aligned to the reference human genome (build hg19) using the Burrows-Wheeler Aligner (BWA-v0.7.15). All variants were subjected to visual inspection. Sequencing and data analysis were performed at BGI (Wuhan, China).
In vivo animal models
We established Raji/Luc lymphoma model via intravenous injection through tail, and CD19-H322/Luc and mutated CD19-H322/Luc solid tumor models via subcutaneous inoculation using 6–8 weeks old female SCID-beige mice. The volume of these cells (1×106) per injection was 100 µL. Thereafter, 1×107 CAR-T cells were resuspended in PBS and injected through the tail vein. Then, the tumor burdens were evaluated by BLI.
All the data were analyzed using Prism V.7.0 (GraphPad Software) and SPSS V.17.0 software. Paired or unpaired two-tailed t-tests were performed to analyze the cytotoxicity of CAR-T cells. Survival curves were analyzed using the log-rank test. Statistical significance was defined as p<0.05.
Clinical characteristics of the CD19+ relapsed patient
Patient 1 who was diagnosed with HGBCL showed progression after chemotherapy with R-CHOP, and Hyper CVAD A and B regimen. However, she was found to be refractory to other regimens, including MA (methotrexate and cytarabine), alternating IVAC (etoposide, ifosfamide, cytarabine), and combined treatment with intrathecal injection two times per cycle (methotrexate, cytarabine, and dexamethasone). Approximately 77.6% and 88.4% clonal mature B lymphocytes were found to persist in her bone marrow and cerebrospinal fluid, respectively. Thereafter, she was enrolled in a clinical trial of BinD19, which included treatment with a CD19-directed CAR (FMC63)-T cell product. Following lymphodepletion, she was infused (splitting with dose escalation) with 2.23×108 total T cells, comprising 2.18×107 CAR-T cells for over 3 days. The major therapeutic schedule followed is shown in figure 1A. She had fever on day 3 after infusion of CAR-T cells, as tocilizumab (160 mg), methylprednisolone (40 mg), and dexamethasone (10 mg) were administered repeatedly to control cytokine release syndrome. PET-CT scan images revealed multiple lymphadenopathy and elevated standard uptake values in the breast, uterus, bilateral ovary, liver, bones, and subcutaneous mass before treatment (figure 1B). After infusion of CAR-T cells, she achieved CR by day 60. However, the CD19+ relapse occurred in her left breast on day 180. She then received two times the amount of anti-programmed cell death protein 1 therapy and eventually the augmented tumor mass was removed by surgical resection. This patient recovered and exhibited CR state by April 2020 (figure 1A,B).
Kinetics of CAR-T and B cells in vivo
We assessed CD3+ CAR-T cells by flow cytometry in blood sample of patient obtained after infusion. The proliferative burst of CAR-T cells was apparent on day 14 (10.8%) and these cells still persisted until day 180 (3.1 %), which is the period of relapse (figure 1C). After PD-1 blocking therapy and surgery, this patient achieved CR again and the percentage of CAR-T cells was 1.4% and 1.1% in peripheral blood and bone marrow, respectively (day 579, figure 1C). Meanwhile, the expansion and long persistence of CAR-T cells were confirmed via quantitative real-time (qRT)-PCR using CAR-specific primers (figure 1D). We also observed a directed relationship between in vivo CAR-T and abnormal B cells in peripheral blood. Our data indicated that the CD19+ B cells were significantly decreased on day 14 (7.7%) and disappeared on day 28 (figure 1C). Additionally, the proportion of malignant CD19+ B cells in bone marrow was 61.7% at the baseline that rose up to 95.4% on day 7. However, it decreased to 0.3% on day 17 after CAR-T cell infusion (data not shown). At day 180, the patient experienced relapse, as noted by abundant infiltration (84.1%) of CD19+ B cells in the left breast tissues. However, the expression of CD19 was very low in blood (1.0%) and bone marrow (1.2%) (figure 1E). These results suggest that tumor cells could evade CAR-T cell-mediated recognition and clearance, despite the persistence exhibited by CAR-T cells.
Characteristics of CAR-T and B cells derived from patient postrelapse
To further characterize the CAR-T and B cells derived from the patient at different points, RNA-seq was performed (online supplemental table S1,2). Our results showed that the inhibitor markers, such as LAG3, TIGIT, and CTLA-4 exhibited a lower expression level, but the expression of PDCD1 was higher in CAR-T cells at the time of relapse than that of CAR-T cells in pre group (figure 2A). The transcription factors TBX21, ZEB2, and ID2 are critical for T-cell exhaustion in cancer,18 but their expression had no obvious difference in CAR-T cells on days 14 and 180. Meanwhile, the exhausted marker NR4A1 was highly expressed in CAR-T cells on day 180 compared with that in CAR-T cells before infusion and on day 14, while the expression level of memory differentiation related genes such as EOMES and TCF7 was high in CAR-T cells on day 180, as well as the memory stem cell associated genes such as CCR7, FAS (encoding CD95), PTPRC (encoding CD45RA), and SELL (encoding CD62L, figure 2A). Thus, these genes may cause a difference in persistence of CAR-T cells in vivo. Herein, CAR-T cells at the relapse also expressed high level of GZMA, IFN-γ, GZMB, and RPF1, suggesting that these cells might have possessed potential antitumor ability in vivo. To understand the reason of relapse in this patient, we further analyzed the gene profile and mutations in CD19+ B cells derived from bone marrow and tumor tissues. Among the genes whose expression was changed in B cells, some transcription factors captured our attention. For example, the IRF4, MEF2B, BCL6, and TCF3, which are associated with progression of lymphoma, were significantly upregulated on day 180, as well as the B cell receptor (CD79B), Toll like receptor (MYD88), and the NF-kappa B protein (RELA). PRDM1, a master regulator of plasma-cell differentiation, was downregulated in relapsed tumors and its loss may contributed to the poor prognosis of patients.19 Meanwhile, no difference was observed in the expression level of stem cell-related and drug resistance-related genes in bone marrow before and after CAR-T cell therapy (on day 7 and 180, figure 2B).
For further analysis of whether the malignant B cells had a mutation or not, we performed whole-exome sequencing (WES). Interestingly, the p.163 (exon3) R>L site mutation was identified in CD19+ cells (95 %) that were isolated from relapsed tumor tissues (figure 2C). However, the CD19+ cells derived from bone marrow before therapy had no mutation (data not shown). Further functional analysis of CAR-T cells revealed that specific lysis of CD19+ cells derived from bone marrow before treatment was higher than those derived from relapsed tissue, indicating that the relapsed CD19+ B cells could not be eradicated by autologous CAR-T cells (figure 2D). We then constructed CD19 CARs comprising scFV antibody fragments, FMC63 and 21D4, and obtained two types of CD19 CAR-T cells. When compared with FMC63, the 21D4 CAR-T cells exhibited better effector-specific function against mutated CD19+ B cells derived from tumor tissues (figure 2E). In summary, point mutation of CD19 confers resistance to autologous FMC63 CAR-T cells, and sensitivity to 21D4 CAR-T cells.
Cytotoxic effect of FMC63 and 21D4 CAR-T cells
To validate the antigen-specific cytotoxic effect of 21D4 CAR-T cells, we conducted an in vitro experiment. Wild type or mutated (exon3, p.163. R-L) CD19+ H322 and A549 cells expressing luciferase were established and the expression of CD19 can be detected at the similar level in these tumor cells through labeling with anti-CD19 antibody (HIB19, online supplemental figure S1A, B). CAR-T cells were then incubated with the target cells for 24 hours, and H322 and A549 cells as a negative control. Our results showed that both the FMC63 and 21D4 CAR-T cells exhibited a low antitumor activity against H322 and A549 cells (online supplemental figure S2A–C). As shown in figure 3A, FMC63 CAR-T cells demonstrated potent cytotoxicity against CD19+ tumor cells, but not against CD19 mutated cells (10:1, H322-mCD19, 2.90E+07±9.68E+05; A549-mCD19, 2.26E+07±3.23E+06). However, 21D4 CAR-T cells exhibited similar cytotoxicity against both wild type and CD19 mutated cells (10:1, H322-mCD19, 6.25E+06±1.27E+06; A549, 1.11E+07±2.21E+06) at higher E:T ratios (online supplemental figure S2D, figure 3A). Furthermore, the results of CAR-specific lysis assay also supported the higher cytotoxic function of 21D4 CAR-T cells (10:1, 37.9%±5.0%) against CD19 mutated tumor cells than that of FMC63 CAR-T cells (10:1, 19.3%±5.8%). (figure 3B), suggesting that there is a difference between the cytotoxic function of FMC63 and 21D4 CAR-T cells. We next investigated which exon of CD19 is most important for the recognition of CAR-T cells. For this, CD19 exon 1, 2, 3, or 4 was depleted and cloned into pCDH-EF1-IRES-Puro vector. Finally, we obtained four different H322 cell lines with deleted CD19 exon (online supplemental figure S3A, B). Then these cells were cocultured with CAR-T cells at E:T ratio of 10:1. Our results showed that FMC63 CAR-T cells were unable to kill the target cells with 1, 2, or 3 exon deleted, but 21D4 CAR-T cells could still exert an effector specific function against these cells (figure 3C,D). However, neither FMC63 nor 21D4 CAR-T cells could eradicate CD19 positive H322 cells, in which the CD19 exon four was deleted (figure 3C,D). This analysis revealed that the deletion of CD19 exons 1–3 or mutation in exon 3 are sufficient for 21D4 CART-19 cells to exert their cytotoxic function.
21D4 CAR-T cells exhibit enhanced potency against mutated CD19 cells in vivo
Based on the observation that 21D4 CAR-T cells exhibit higher potency against mutated CD19+ cells in vitro, we speculated whether CAR-T cells with different scFVs fragments could exert similar outcomes in vivo. 5×106 Raji/Luc cells were injected through tail vein and simultaneously 1×106 wild type or mutated CD19+-H322/Luc cells were inoculated subcutaneously into the immune-deficient mice 1 week before CAR-T treatment, respectively. Tumor burdens across the different groups were balanced by BLI analyzes before CAR-T infusion. Thereafter, 1×107 CAR-T cells cultured for 10 days were infused to mice via tail, and mock T cells were used as control. Both FMC63 and 21D4 CAR-T cells demonstrated anti-lymphoma activity in all the treated mice on BLI examination compared with that in uninfected T cell-treated mice (figure 4A). Moreover, FMC63 and 21D4 CAR-T cells effectively controlled CD19+ H322 tumor cell growth, while the tumor growth was observed in mice treated with control T cells (figure 4B). We also assessed the antitumor effect of FMC63 and 21D4 CAR-T cells in mutated CD19+ H322 model. As shown in figure 4B,C, 21D4 CAR-T cells significantly controlled mutated CD19+ tumor growth when compared with FMC63 CAR-T cells. Meanwhile, the 21D4 CAR-T cells treated H322-mCD19 mice had a longer overall survival than the mice treated with FMC63 CAR-T cells (figure 4D). These results suggest that there is a difference in effector-specific function of CD19 CAR comprising scFV antibody fragments FMC63 or 21D4.
Antitumor ability of 21D4 CAR-T cells in CD19 mutated patients with B cell lymphoma
Whether this type of mutation appears in patients with NR to CAR-T cell therapy is not clear. Therefore, we further analyzed the mutations in CD19+ cells from two different patients with NR and one patient with CR as a control. The clinical characteristics of these patients are presented in table 1. All of the patients exhibited progression after receiving chemotherapy regimen. Patient 2 was treated according to the anti-CD19 CAR protocol and achieved a CR state in 24 months. Two patients with lymphoma resisted the CAR-T cell therapy and died due to disease progression. We detected CAR-T cells by qRT-PCR analysis in the peripheral blood samples of these patients obtained after infusion and observed an increase in the number of CAR-T cells in these patients (figure 5A). Patient 3 with NR exhibited bone marrow involvement on day 37 and died on day 42 after infusion of CAR-T cells. Patient 4 with NR also died on day 87 after treatment with CAR-T cells. We further found that the percentage of malignant CD19+ B cells in bone marrow or tumor tissues from the two NR patients after CAR-T cell treatment were 85.1% and 99.8%, respectively (data not shown). Additionally, these two patients possessed a point mutation in exon 3 of CD19 (p.174 L>V, figure 5B). However, the patient with CR had no such mutation. Further analysis revealed that 21D4 CAR-T cells exhibit better effector-specific function compared with FMC63 CAR-T cells when co-cultured with CD19+ cells from patients with NR (figure 5C). Altogether, the patients possessing point mutation in CD19+ cells (exon 3, p.174 L>V) might exhibit resistance to CD19 CAR-T cell therapy, and these mutated cells can be effectively eradicated by 21D4 CAR-T cells.
CD19-based immunotherapy has changed the pattern of treatment of relapsed or refractory B cell lymphomas.20–22 Patients with a previously unsatisfactory outcome have now been reported to achieve CR and long-term disease remission.23 However, clinical data have revealed that a subset of lymphoma or B-ALL patients that achieves remission subsequently undergoes relapse. Our clinical trial with FMC63-CD19 CAR supports the fact that some patients exhibited relapse and resistance after the treatment. Our results showed that infusing cells against lymphoma is effective and safe. One patient with HGBCL received autologous CD19 CAR-T cell therapy. We observed that the number of CAR-T cells in the blood rapidly increased on day 14 and decreased after eliminating the tumor cells on day 28 as detected by flow cytometry. Meanwhile, the CD19+ cells were found to be significantly decreased on day 14 and disappeared by day 28 after CAR-T cell infusion. This finding is similar with the mechanism of T cell activation because higher CAR-T cell activity against target cells may enhance the responses of effector T cells and stimulate CAR-T cell proliferation. It is noticeable that CAR-T cells in this patient were durable and persisted in vivo, but the left breast tumor tissue was found to express 84.1% CD19 protein on day 180, indicating a CD19+ recurrence of this patient. Moreover, this CD19+ relapse was also verified by immunohistochemical analysis in the department of pathology (data not shown). The number of CAR-T cells was slightly increased at this stage of recurrence, and then decreased to 0.6% (at day 579) after the tumor was removed by surgery in combination with anti-PD-1 therapy. However, CAR-T cells increased in number in the first 14 days and rapidly disappeared in the two patients with NR, suggesting that these patients initially resisted the treatment.
Recent studies have reported that the reasons of relapse includes CAR-T cell persistence and loss or downregulation of the targeted CD19 antigens.23 Elena et al have reported the underlying mechanism of resistance to CD19 CAR-T cells and suggested that exon 2 of CD19 is frequently spliced out, leading to the inhibition of CD19 protein expression. Moreover, the acquired genetic mutations in CD19 exons 2–5 are the major mechanisms of CD19 loss. Ramakrishna et al also found that low target antigen expression negatively impacts the in vitro and in vivo CAR-T cell functionality and impairs in vivo persistence of CAR-T cells.24 To identify the reason behind the immune escape from CAR-T cells in the patient exhibiting CD19+ relapse, we first compared the expression of transcription factors, inhibitory markers, and genes associated with cytotoxicity in CAR-T cells before and after infusion. Our results indicated that functional CAR-T cells persisted in blood until recurrence. We further analyzed the molecular characteristics and mutations of B cells. The relapsed CD19+ cells expressed transcription factors at high levels. For example, the expression IRF4, a member of the interferon regulatory factor family, which is associated with the progression of lymphoma, was increased.25 MEF2B, the most divergent and least studied protein of the MEF2 family, has a unique role in non-Hodgkin lymphomas.26 The combination of MYC and/or BCL2 with BCL6 in lymphoma has been linked to unfavorable clinical outcomes.27 The expression level of other genes such as CD79B, MYD88 and RELA were also high on day 180, which may be associated with the development of lymphoma.28 29 Next-generation sequencing of DNA from CD19+ cells in relapsed tumor tissues revealed that this patient had a mutation on exon 3 of CD19 (p.163. R-L), but it was not detected in the CD19+ cells from bone marrow prior to CAR-T cell therapy. The other patients with CR (4/14) had no relapse after autologous CD19 CAR-T cell therapy in our clinical trial,30 and one of these patients exhibited no mutation in CD19+ cells before treatment. For the patients with CD19– relapse, various mutations were detected in CD19 isolated from bone marrow DNA. However, these mutations were not detectable before CAR-T cell treatment. Orlando et al sequenced samples collected at various time points during treatment, and they demonstrated that the genetic variants at relapse were not detectable in the specimens before relapse.11 This treatment failure was due to growth of clones with CD19 mutations, which led to a decrease in the expression of CD19 protein on the surface of cells that were under selective pressure from CAR-T cells.31 Moreover, each relapsed patient with ALL has different mutations, and 4/5 patients had the mutation on exon 3. The data suggest that patients who received CAR-T cell therapy might be prone to mutation on exon 3. The mutation identified in CD19+ relapse patient in our study was also different from any other CD19– relapse mutation that reported before, but it also occurred in exon 3.11 The two patients with NR acquired the mutation in CD19 (p.174 (exon3) L>V) on 1 month after infusion with CD19 CAR-T cells. It is a pity for that the samples can’t be obtained before and after treatment to perform WES. Whether the selective pressure from CAR-T cells can lead to outgrowth of clones with this CD19 mutations in NR patients or not is still unclear. We further found that the FMC63 CAR-T cells could kill the wild type CD19+ cells, but not of the mutated CD19+ cells derived from tumor tissues or bone marrow. These data indicate that CD19 mutation may contribute to the immune escape.
Interestingly, most of patients with ALL continued to generate CD22+ cells at the time of relapse. Therefore, the application of CD22 CAR-T cells could be a promising treatment strategy.32–34 Alternatively, CAR engineering could be used to enhance the affinity of the scFv activity against tumor cells with low antigen density. It indicates that by altering the affinity of EGFR and/or HER2 CARs, it is possible to recognize as low levels of antigens as expressed on a normal tissue. However, a research group demonstrated that CD22 CAR-T cells with high affinity become terminally differentiated when stimulated by CD22low leukemia cells and exhibited no improvement in function.24 There are limited strategies that can be implemented for the treatment of patients with CD19+ mutations. In our study, we compared the effector-specific function of FMC63 and 21D4 CAR-T cells against the mutated CD19 tumor cells. Our results showed that 21D4 CAR-T cells had a potent cytotoxic effect against the mutated CD19+ cells (p.163 R>L) both in vitro and in vivo. Further analysis revealed that 21D4 CAR-T cells also can eradicate CD19+ cells with p.174 (exon3) L>V mutation. Previous reports have shown that the epitope recognized by FMC63 containing the residues, which are distant at sequence but proximal at space.35 Hence, the epitopes of CD19 are complicated in terms of antibody recognition. Moreover, the affinity of antibody may play a key role in impacting the CAR-T cell response. Recently, the epitope of 21D4 still remains unknown. To compare the functional differences between FMC63 and 21D4 CAR-T cells, we constructed CD19+ cells with deleted exon 1, 2, 3, or 4. HIB19 can be completely blocked the binding of FMC63 to cells by competitive binding experiments, suggesting that FMC63 and HIB19 may bind to the same or overlapping epitopes on CD19.12 36 We found that in the exon deleted cells, the expression of CD19 was not changed at transcriptional level, but was significantly decreased at protein level (testing by HIB19, data not shown). Our data also revealed that 21D4 CAR-T cells possess high antitumor capacity for the eradication of CD19+ cells with exon 1, 2, or 3 deletion, while FMC63 CAR-T cells could not exert the same effect on the target cells. Our results suggest that these two kinds of CAR-T cells may possess different binding sites for CD19. Based on these findings, we suggest that 21D4 CAR-T cells may be applied as an individualized treatment strategy for some recurrent patients with point mutation in CD19+ cells.
In summary, FMC63 CAR-T cells showed limited cytotoxic efficacy in patients with CD19 mutations, leading to relapse after the CAR-T cell therapy. Interestingly, 21D4 CAR-T cells could exert cytotoxic effect on B cells with CD19 mutations both in vitro and in vivo, which may thus provide an alternative strategy for establishing a treatment for lymphoma patients with CD19 mutations.
We thank the patients and healthy donors for their signed informed consent forms in this experiment.
ZZ, XC and YT contributed equally.
Contributors YZ: designed research; ZZ, YT, FL, and CY: performed experiments, data collection, and statistical analyses; XC and XZ: enrolled patients; YZ and JL: revised the manuscript; and all authors were approved the final version.
Funding This study was supported by the National Key Research and Development Program of China (No. 2018YFC1313400) and the National Natural Science Foundation of China (Grant No. U1804281, 81771781, and 81702810).
Competing interests None declared.
Patient consent for publication Not required.
Ethics approval All the volunteer and patient were recruited, following the approval by the Ethics Committee Board of the First Affiliated Hospital of Zhengzhou University. Animal studies were approved by the Animal Care and Ethics Committee of the First Affiliated Hospital of Zhengzhou University.
Provenance and peer review Not commissioned; externally peer reviewed.
Data availability statement No data are available.